KYM Biosciences

KYM is a joint venture established by Keymed Biosciences (which holds 70% ownership of KYM) and Lepu Biopharma (which holds 30% ownership of KYM). Keymed Biosciences develops innovative monoclonal antibody drugs and other therapeutic protein drugs targeting major diseases.